Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Gan & Lee Pharmaceuticals Co. Ltd. manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This prosecution involves 1 distinct examiner and is situated within 1 distinct art unit. The narrow scope of current activity suggests a focused patenting effort in this specific technical field, with all current examination concentrated in one area. This allows the company to dedicate its resources to a single technical conversation with the patent office.
COFFA, SERGIO is the busiest examiner for the company, currently handling 1 pending office action. This action constitutes the entirety of the pending workload for the portfolio. Because the activity is limited to 1 distinct art unit, the prosecution is currently confined to a single specialized group within the patent office. This concentration allows the company to focus its prosecution resources on the specific requirements and trends of this individual examiner and art unit. Practitioners should note that such a focused portfolio requires a deep understanding of the specific art unit's precedents to successfully navigate the 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COFFA, SERGIO | 1 | 61.1% | +32.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18571461 | Acylated Insulin-Containing Pharmaceutical Composition | COFFA, SERGIO | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18571461 | Acylated Insulin-Containing Pharmaceutical Composition | COFFA, SERGIO | 1658 | §103§112DP | Non-Final OA | — | Pending | Dec 18, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGan & Lee Pharmaceuticals Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sergio Coffa has the most, with 1 of Gan & Lee Pharmaceuticals Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
